

Table SI. Univariate and multivariable Cox regression analyses of overall survival.

Variable	Univariate analysis		Multivariate analysis	
	P-value	HR (95% CI)	P-value	HR (95% CI)
<i>KRAS</i> mutation	0.023	1.593 (1.065-2.382)	0.001	2.490 (1.427-4.343)
Age, years (≥ 60 vs. < 60)	0.384	1.198 (0.797-1.801)	0.001	2.407 (1.405-4.122)
Sex (Male vs. Female)	0.455	1.171 (0.773-1.773)	0.871	0.957 (0.564-1.625)
Grade of regression after neoadjuvant therapy	0.221		0.062	
Minimal vs. Not received	0.184	1.755 (0.766-4.022)	0.036	3.255 (1.081-9.800)
Moderate vs. Not received	0.561	1.307 (0.529-3.232)	0.513	1.509 (0.440-5.173)
Near total vs. Not received	0.111	5.021 (0.691-36.465)	0.081	11.299 (0.744-17.170)
Tumor location (Left vs. Right)	0.016	0.590 (0.384-0.907)	0.036	0.524 (0.286-0.960)
Tumor size, cm (≥ 5 vs. < 5)	0.025	1.586 (1.059-2.375)	0.007	1.931 (0.747-4.993)
T stage	< 0.001		0.472	
T1 vs. Tis	0.527	0.461 (0.042-5.084)	0.319	14.077 (0.780-25.458)
T2 vs. Tis	0.551	1.854 (0.244-14.110)	0.170	30.832 (0.231-41.219)
T3 vs. Tis	0.804	1.285 (0.177-9.338)	0.110	45.887 (0.422-49.846)
T4 vs. Tis	0.177	3.930 (0.538-28.707)	0.133	34.703 (0.338-35.583)
N stage	< 0.001		0.174	
N1 vs. N0	0.431	1.265 (0.705-2.269)	0.191	0.622 (0.305-1.268)
N2 vs. N0	< 0.001	3.076 (1.864-5.076)	0.793	1.100 (0.541-2.236)
M stage (M1 vs. M0)	< 0.001	7.725 (4.615-12.931)	< 0.001	7.304 (3.493-15.273)
TNM stage	< 0.001		0.001	
Stage I vs. Stage 0	0.568	0.517 (0.054-4.973)	0.340	0.302 (0.026-3.530)
Stage II vs. Stage 0	0.537	0.508 (0.059-4.353)	0.171	0.188 (0.017-2.059)
Stage III vs. Stage 0	0.421	0.425 (0.053-3.404)	0.147	0.157 (0.013-1.912)
Stage IV vs. Stage 0	0.172	3.961 (0.550-28.499)	0.072	19.318 (0.772-48.359)
TP53 expression, % (≥ 50 vs. < 50)	0.005	4.267 (1.539-11.829)	0.560	1.518 (0.373-6.187)
Infiltrative tumor border, % (≥ 50 vs. < 50)	0.051	2.481 (0.995-6.187)	0.306	1.741 (0.602-5.033)
Tumor differentiation	0.006		0.593	
Moderate vs. Well	0.225	1.508 (0.777-2.927)	0.781	1.124 (0.492-2.568)
Poor vs. Well	0.004	3.221 (1.460-7.104)	0.326	1.865 (0.538-6.460)
Cribriform pattern	0.047		0.559	
Mild vs. Absent	0.994	0.998 (0.587-1.696)	0.791	0.906 (0.438-1.874)
Moderate vs. Absent	0.047	0.441 (0.196-0.989)	0.344	0.603 (0.212-1.718)
Serrated pattern	0.329		0.694	
Mild vs. Absent	0.159	0.739 (0.485-1.126)	0.421	0.782 (0.430-1.423)
Moderate vs. Absent	0.966	1.016 (0.494-2.087)	0.987	1.008 (0.393-2.586)
Quality of mucin	0.133		0.184	
Low-grade vs. Absent	0.184	1.395 (0.854-2.281)	0.398	1.471 (0.601-3.601)
High-grade vs. Absent	0.088	1.838 (0.914-3.694)	0.225	0.439 (0.116-1.661)
Q score of mucin (≥ 60 vs. < 60)	0.136	1.585 (0.865-2.903)	0.076	3.980 (1.028-15.412)
Signet ring cells (Present vs. Absent)	< 0.001	3.000 (1.633-5.511)	0.953	0.963 (0.270-3.432)
Solid component, % (≥ 50 vs. < 50)	0.593	1.141 (0.703-1.852)	0.491	1.291 (0.624-2.671)
Papillary component (Present vs. Absent)	0.095	1.510 (0.930-2.450)	0.797	0.917 (0.473-1.776)
Micropapillary component (Present vs. Absent)	0.135	0.728 (0.480-1.104)	0.617	0.860 (0.476-1.554)
Crohn's-like lymphoid reaction (Moderate vs. Absent to mild)	0.009	0.517 (0.316-0.847)	0.228	0.670 (0.349-1.285)
Dirty necrosis	< 0.001		0.740	
Low vs. Absent	0.051	0.560 (0.313-1.002)	0.349	0.676 (0.298-1.534)
Moderate vs. Absent	0.000	0.323 (0.176-0.594)	0.972	1.016 (0.419-2.464)
High vs. Absent	0.001	0.290 (0.141-0.597)	0.722	1.221 (0.407-3.656)
Confluent vs. Absent	0.000	0.277 (0.141-0.541)	0.958	1.029 (0.351-3.018)
Neutrophilic infiltration	0.003		0.661	
Low vs. Absent	0.004	0.473 (0.284-0.788)	0.294	0.683 (0.335-1.392)
Focal vs. Absent	0.012	0.498 (0.289-0.858)	0.925	1.034 (0.520-2.057)
Numerous vs. Absent	0.003	0.393 (0.212-0.727)	0.947	0.972 (0.422-2.237)

Table SI. Continued.

Variable	Univariate analysis		Multivariate analysis	
	P-value	HR (95% CI)	P-value	HR (95% CI)
Tumor-infiltrating lymphocytes, % (≥ 50 vs. < 50)	0.072	0.636 (0.388-1.041)	0.657	1.147 (0.625-2.106)
Tumor budding grade	0.050		0.021	
Intermediate vs. Low	0.145	1.417 (0.887-2.263)	0.008	2.192 (1.224-3.925)
High vs. Low	0.019	1.851 (1.106-3.100)	0.073	2.172 (0.930-5.075)
Lymphatic invasion	0.001	2.491 (1.428-4.348)	0.804	1.087 (0.563-2.099)
Vascular invasion	< 0.001	3.504 (1.930-6.362)	0.049	2.002 (1.004-3.989)
Perineural invasion	< 0.001	3.359 (2.050-5.506)	0.012	2.163 (1.187-3.939)

HR, hazard ratio; CI, confidence interval; T, tumor; N, nodes; M, metastasis; TNM, tumor-node-metastasis.

Table SII. Univariate and multivariable Cox regression analysis of disease-free survival.

Variables	Univariate analysis		Multivariate analysis	
	P-value	HR (95% CI)	P-value	HR (95% CI)
KRAS mutation	0.611	1.097 (0.769-1.564)	0.365	1.221 (0.793-1.878)
Age, years (≥ 60 vs. < 60)	0.254	0.817 (0.577-1.156)	0.897	0.973 (0.638-1.482)
Sex (Male vs. Female)	0.052	1.434 (0.997-2.062)	0.599	1.119 (0.736-1.699)
Grade of regression after neoadjuvant therapy	0.206		0.349	
Minimal vs. Not received	0.040	2.046 (1.035-4.043)	0.147	1.839 (0.808-4.186)
Moderate vs. Not received	0.786	1.132 (0.462-2.772)	0.874	0.914 (0.299-2.792)
Near total vs. Not received	0.541	1.849 (0.258-13.250)	0.301	3.762 (0.306-46.193)
Tumor location (Left vs. Right)	0.449	0.862 (0.586-1.267)	0.850	0.957 (0.607-1.508)
Tumor size, cm (≥ 5 vs. < 5)	0.025	1.490 (1.051-2.112)	0.507	1.144 (0.769-1.703)
T stage	0.001		0.922	
T1 vs. Tis	0.564	0.494 (0.045-5.446)	0.391	7.481 (0.076-73.902)
T2 vs. Tis	0.401	2.372 (0.315-17.846)	0.470	4.941 (0.065-37.525)
T3 vs. Tis	0.447	2.152 (0.299-15.511)	0.417	5.816 (0.083-4.088)
T4 vs. Tis	0.143	4.407 (0.605-32.125)	0.429	5.639 (0.077-41.192)
N stage	< 0.001		0.689	
N1 vs. N0	0.002	2.248 (1.360-3.717)	0.392	1.290 (0.720-2.311)
N2 vs. N0	0.000	3.080 (1.916-4.951)	0.624	1.151 (0.655-2.022)
M stage (M1 vs. M0)	< 0.001	25.159 (12.450-50.845)	< 0.001	24.174 (10.614-55.057)
TNM stage	< 0.001		0.272	
Stage I vs. Stage 0	0.240	0.190 (0.012-3.039)	0.172	0.056 (0.001-3.486)
Stage II vs. Stage 0	0.218	0.221 (0.020-2.438)	0.132	0.059 (0.002-2.342)
Stage III vs. Stage 0	0.852	0.824 (0.108-6.304)	0.392	0.245 (0.010-6.146)
Stage IV vs. Stage 0	0.008	15.723 (2.041-12.144)	0.005	10.334 (1.563-14.819)
TP53 expression, % (≥ 50 vs. < 50)	0.553	1.417 (0.448-4.479)	0.948	0.955 (0.235-3.872)
Infiltrative tumor border, % (≥ 50 vs. < 50)	0.249	1.428 (0.779-2.616)	0.775	1.116 (0.526-2.367)
Tumor differentiation	0.106		0.958	
Moderate vs. Well	0.106	1.612 (0.903-2.878)	0.775	0.901 (0.441-1.841)
Poor vs. Well	0.035	2.161 (1.058-4.415)	0.839	0.897 (0.313-2.567)
Cribriform pattern	0.107		0.702	
Mild vs. Absent	0.173	1.432 (0.854-2.400)	0.481	1.272 (0.651-2.483)
Moderate vs. Absent	0.714	0.880 (0.445-1.742)	0.849	1.089 (0.455-2.606)
Serrated pattern	0.898		0.768	
Mild vs. Absent	0.660	0.922 (0.641-1.326)	0.507	1.180 (0.723-1.925)
Moderate vs. Absent	0.786	0.911 (0.463-1.792)	0.594	1.245 (0.556-2.788)
Quality of mucin	0.118		0.887	
Low-grade vs. Absent	0.514	1.159 (0.744-1.806)	0.648	1.164 (0.607-2.232)
High-grade vs. Absent	0.041	1.801 (1.024-3.166)	0.741	1.179 (0.444-3.130)
Q score of mucin (≥ 60 vs. < 60)	0.361	1.285 (0.750-2.202)	0.723	1.191 (0.454-3.126)
Signet ring cells (Present vs. Absent)	0.006	2.137 (1.244-3.671)	0.954	1.029 (0.392-2.699)
Solid component, % (≥ 50 vs. < 50)	0.747	0.930 (0.601-1.440)	0.782	0.919 (0.507-1.667)
Papillary component (Present vs. Absent)	0.349	0.843 (0.589-1.205)	0.804	0.942 (0.588-1.509)
Micropapillary component (Present vs. Absent)	0.059	1.499 (0.985-2.280)	0.711	1.107 (0.648-1.891)
Crohn's-like lymphoid reaction (Moderate vs. Absent to mild)	0.038	0.649 (0.431-0.977)	0.205	0.712 (0.422-1.203)
Dirty necrosis	0.338		0.995	
Low vs. Absent	0.744	0.912 (0.525-1.585)	0.852	0.938 (0.478-1.840)
Moderate vs. Absent	0.212	0.702 (0.403-1.224)	0.695	0.860 (0.405-1.826)
High vs. Absent	0.124	0.596 (0.309-1.151)	0.701	0.838 (0.341-2.064)
Confluent vs. Absent	0.134	0.637 (0.354-1.149)	0.778	0.884 (0.376-2.079)
Neutrophilic infiltration	0.001		0.870	
Low vs. Absent	0.004	0.530 (0.343-0.818)	0.674	0.886 (0.503-1.559)
Focal vs. Absent	0.002	0.465 (0.287-0.754)	0.410	0.783 (0.438-1.400)
Numerous vs. Absent	0.003	0.442 (0.257-0.759)	0.632	0.846 (0.425-1.681)

Table SII. Continued.

Variables	Univariate analysis		Multivariate analysis	
	P-value	HR (95% CI)	P-value	HR (95% CI)
Tumor-infiltrating lymphocytes, % (≥ 50 vs. < 50)	0.013	0.570 (0.365-0.889)	0.297	0.765 (0.462-1.266)
Tumor budding grade	0.632		0.618	
Intermediate vs. Low	0.672	1.092 (0.728-1.638)	0.673	1.110 (0.683-1.806)
High vs. Low	0.345	1.255 (0.783-2.010)	0.327	1.446 (0.692-3.022)
Lymphatic invasion	< 0.001	2.328 (1.488-3.642)	0.986	0.995 (0.542-1.823)
Vascular invasion	0.001	2.406 (1.436-4.033)	0.436	1.311 (0.663-2.590)
Perineural invasion	0.009	1.753 (1.151-2.670)	0.720	0.902 (0.515-1.582)

HR, hazard ratio; CI, confidence interval; TNM, tumor-node-metastasis.

Table SIII. The result of univariate analysis on overall survival according to *KRAS* mutation status

Characteristics	<i>KRAS</i> -mutated		Wild type	
	P-value	HR (95% CI)	P-value	HR (95% CI)
Age, years (≥ 60 vs. < 60)	0.785	1.086 (0.600-1.964)	0.267	1.382 (0.780-2.449)
Sex (Male vs. Female)	0.090	1.718 (0.920-3.210)	0.712	0.900 (0.514-1.576)
Tumor location (Left vs. Right)	0.540	0.821 (0.438-1.541)	0.021	0.498 (0.276-0.899)
Tumor size, cm (≥ 5 vs. < 5)	0.030	1.932 (1.064-3.508)	0.189	1.448 (0.834-2.513)
T stage (T4 vs. T3 vs. T2 vs. T1 vs. Tis)	0.017	1.663 (1.095-2.526)	0.004	1.831 (1.218-2.751)
N stage (N2 vs. N1 vs. N0)	< 0.001	2.250 (1.526-3.317)	0.003	1.682 (1.188-2.381)
M stage (M1 vs. M0)	< 0.001	7.180 (3.589-14.364)	< 0.001	9.987 (4.491-22.207)
TNM stage (IV vs. III vs. II vs. I vs. 0)	< 0.001	2.427 (1.633-3.607)	< 0.001	5.265 (2.734-10.141)
Infiltrative tumor border, % (≥ 50 vs. < 50)	0.824	1.129 (0.389-3.276)	0.046	7.543 (1.033-55.046)
Tumor differentiation (Poor vs. Moderate vs. Well)	0.070	1.805 (0.953-3.419)	0.006	2.164 (1.250-3.747)
Cribiform pattern (Moderate vs. Mild vs. Absent)	0.654	1.126 (0.671-1.890)	0.006	0.527 (0.332-0.835)
Serrated pattern (Moderate vs. Mild vs. Absent)	0.261	0.763 (0.476-1.223)	0.623	0.887 (0.549-1.432)
Signet ring cells (Present vs. Absent)	0.021	3.992 (1.229-12.963)	0.002	3.191 (1.546-6.588)
Solid component, % (≥ 50 vs. < 50)	0.074	1.956 (0.937-4.087)	0.871	0.948 (0.497-1.808)
Papillary component (Present vs. Absent)	0.265	0.712 (0.392-1.294)	0.169	0.661 (0.366-1.193)
Micropapillary component (Present vs. Absent)	0.599	1.229 (0.569-2.652)	0.078	1.760 (0.939-3.300)
Quality of mucin	0.099		0.459	
Low-grade vs. Absent	0.651	1.169 (0.594-2.299)	0.303	1.466 (0.708-3.034)
High-grade vs. Absent	0.032	3.200 (1.108-9.237)	0.397	1.498 (0.588-3.821)
Q score of mucin (≥ 60 vs. < 60)	0.378	1.590 (0.567-4.460)	0.154	1.731 (0.814-3.682)
Crohn's-like lymphoid reaction (Moderate vs. Absent to mild)	0.020	0.383 (0.171-0.860)	0.166	0.641 (0.342-1.202)
Dirty necrosis (Confluent vs. High vs. Moderate vs. Low vs. Absent)	0.021	0.751 (0.590-0.957)	0.002	0.702 (0.561-0.877)
Neutrophilic infiltration (Numerous vs. Focal vs. low vs. Absent)	0.002	0.617 (0.453-0.840)	0.041	0.752 (0.572-0.989)
Tumor-infiltrating lymphocytes, % (≥ 50 vs. < 50)	0.360	0.699 (0.325-1.505)	0.178	0.642 (0.336-1.224)
Tumor budding grade (High vs. Intermediate vs. Low)	0.593	1.112 (0.753-1.641)	0.005	1.606 (1.153-2.237)

HR, hazard ratio; CI, confidence interval; TNM, tumor-node-metastasis.

Table SIV. The result of univariate analysis on disease-free survival according to *KRAS* mutation status

Characteristics	<i>KRAS</i> -mutated		Wild type	
	P-value	HR (95% CI)	P-value	HR (95% CI)
Age, years (≥ 60 vs. < 60)	0.417	0.793 (0.453-1.388)	0.459	0.844 (0.538-1.323)
Sex (Male vs. Female)	0.339	1.322 (0.746-2.341)	0.083	1.517 (0.947-2.429)
Tumor location (Left vs. Right)	0.770	0.916 (0.510-1.645)	0.503	0.838 (0.500-1.406)
Tumor size, cm (≥ 5 vs. < 5)	0.121	1.552 (0.890-2.709)	0.090	1.476 (0.942-2.313)
T stage (T4 vs. T3 vs. T2 vs. T1 vs. Tis)	0.032	1.502 (1.035-2.179)	0.001	1.715 (1.243-2.365)
N stage (N2 vs. N1 vs. N0)	< 0.001	2.292 (1.560-3.367)	0.005	1.470 (1.121-1.927)
M stage (M1 vs. M0)	< 0.001	18.348 (5.920-56.866)	< 0.001	41.856 (14.671-119.412)
TNM stage (IV vs. III vs. II vs. I vs. 0)	< 0.001	4.270 (2.316-7.873)	< 0.001	25.146 (9.041-69.937)
Infiltrative tumor border, % (≥ 50 vs. < 50)	0.632	1.262 (0.487-3.270)	0.276	1.548 (0.705-3.401)
Tumor differentiation (Poor vs. Moderate vs. Well)	0.153	1.533 (0.853-2.755)	0.086	1.457 (0.948-2.239)
Cribiform pattern (Moderate vs. Mild vs. Absent)	0.515	1.179 (0.718-1.935)	0.375	0.846 (0.585-1.224)
Serrated pattern (Moderate vs. Mild vs. Absent)	0.306	0.789 (0.501-1.242)	0.893	1.026 (0.706-1.492)
Signet ring cells (Present vs. Absent)	0.114	2.292 (0.818-6.419)	0.020	2.132 (1.124-4.042)
Solid component, % (≥ 50 vs. < 50)	0.379	1.383 (0.672-2.847)	0.397	0.788 (0.455-1.366)
Papillary component (Present vs. Absent)	0.253	0.720 (0.410-1.265)	0.691	0.910 (0.571-1.450)
Micropapillary component (Present vs. Absent)	0.063	1.852 (0.966-3.553)	0.333	1.312 (0.757-2.274)
Quality of mucin	0.553		0.191	
Low-grade vs. Absent	0.504	1.239 (0.661-2.323)	0.889	1.047 (0.549-1.997)
High-grade vs. Absent	0.333	1.672 (0.591-4.733)	0.070	1.864 (0.951-3.653)
Q score of mucin (≥ 60 vs. < 60)	0.959	1.027 (0.370-2.853)	0.272	1.430 (0.756-2.705)
Crohn's-like lymphoid reaction (Moderate vs. Absent to mild)	0.033	0.438 (0.205-0.934)	0.358	0.794 (0.484-1.300)
Dirty necrosis (Confluent vs. High vs. Moderate vs. Low vs. Absent)	0.090	0.827 (0.665-1.030)	0.271	0.910 (0.769-1.076)
Neutrophilic infiltration (Numerous vs. Focal vs. Low vs. Absent)	0.004	0.650 (0.486-0.868)	0.027	0.779 (0.624-0.972)
Tumor-infiltrating lymphocytes, % (≥ 50 vs. < 50)	0.373	0.720 (0.350-1.483)	0.018	0.507 (0.288-0.892)
Tumor budding grade (High vs. Intermediate vs. Low)	0.484	1.137 (0.794-1.628)	0.514	1.102 (0.824-1.474)

HR, hazard ratio; CI, confidence interval; TNM, tumor-node-metastasis.

Table SV. The result of multivariate analysis on disease-free survival according to *KRAS* mutation status

Characteristics	<i>KRAS</i> -mutated		Wild type	
	P-value	HR (95% CI)	P-value	HR (95% CI)
Age, years (≥ 60 vs. < 60)	0.719	1.178 (0.482-2.880)	0.989	0.996 (0.543-1.825)
Sex (Male vs. Female)	0.596	1.233 (0.568-2.673)	0.762	1.093 (0.615-1.942)
Tumor location (Left vs. Right)	0.844	0.918 (0.392-2.152)	0.960	1.016 (0.545-1.893)
Tumor size, cm (≥ 5 vs. < 5)	0.415	1.359 (0.650-2.841)	0.637	1.147 (0.649-2.026)
M stage (M1 vs. M0)	< 0.001	15.471 (3.399-70.418)	< 0.001	47.913 (14.197-161.70)
Infiltrative tumor border, % (≥ 50 vs. < 50)	0.560	0.698 (0.209-2.333)	0.886	1.069 (0.432-2.646)
Tumor differentiation (Poor vs. Moderate/Well)	0.824	0.841 (0.184-3.843)	0.789	1.128 (0.465-2.736)
Cribriform pattern	0.794		0.862	
Mild vs. Absent	0.694	1.286 (0.367-4.509)	0.823	1.093 (0.503-2.375)
Moderate vs. Absent	0.948	0.946 (0.178-5.036)	0.818	0.887 (0.319-2.464)
Serrated pattern	0.505		0.780	
Mild vs. Absent	0.504	1.315 (1.315-0.589)	0.486	1.257 (0.661-2.390)
Moderate vs. Absent	0.253	2.225 (0.564-8.768)	0.720	1.236 (0.389-3.931)
Signet ring cells (Present vs. Absent)	0.785	0.729 (0.075-7.055)	0.749	1.204 (0.386-3.752)
Solid component, % (≥ 50 vs. < 50)	0.968	0.978 (0.340-2.817)	0.462	0.753 (0.353-1.605)
Papillary component (Present vs. Absent)	0.763	0.871 (0.353-2.146)	0.773	0.903 (0.451-1.808)
Micropapillary (Present vs. Absent)	0.068	2.637 (0.931-7.469)	0.965	1.017 (0.482-2.146)
Quality of mucin	0.655		0.999	
Low-grade vs. Absent	0.358	1.712 (0.543-5.393)	0.962	1.025 (0.377-2.783)
High-grade vs. Absent	0.952	1.112 (0.000-3.186)	0.994	1.004 (0.320-3.149)
Q score of mucin (≥ 60 vs. < 60)	0.946	0.000 (0.000-5.762)	0.431	1.656 (0.472-5.806)
Crohn's-like lymphoid reaction (Moderate vs. Absent to mild)	0.083	0.356 (0.111-1.144)	0.591	0.839 (0.441-1.594)
Dirty necrosis	0.725		0.943	
Low vs. absent	0.461	0.626 (0.181-2.172)	0.811	1.118 (0.449-2.784)
Moderate vs. Absent	0.980	1.018 (0.240-4.324)	0.733	0.830 (0.286-2.412)
High vs. Absent	0.805	0.838 (0.206-3.414)	0.725	0.779 (0.194-3.132)
Confluent vs. Absent	0.414	0.445 (0.064-3.094)	0.975	0.983 (0.328-2.947)
Neutrophilic infiltration	0.563		0.970	
Low vs. Absent	0.947	0.963 (0.313-2.960)	0.761	0.870 (0.354-2.135)
Focal vs. Absent	0.310	0.568 (0.191-1.693)	0.959	0.979 (0.445-2.158)
Numerous vs. Absent	0.389	0.480 (0.090-2.548)	0.633	0.800 (0.320-1.999)
Tumor-infiltrating lymphocytes, % (≥ 50 vs. < 50)	0.425	0.685 (0.270-1.737)	0.493	0.784 (0.392-1.571)
Tumor budding grade	0.667		0.965	
Intermediate vs. Low	0.952	1.026 (0.451-2.331)	0.794	1.101 (0.533-2.277)
High vs. Low	0.393	2.028 (0.400-10.273)	0.947	1.035 (0.368-2.912)

HR, hazard ratio; CI, confidence interval.